Source: iQoncept / Shutterstock
ImmunityBio (NASDAQ:IBRX) just reported results for the first quarter of 2024.
- ImmunityBio reported earnings per share of -20 cents. This was below the analyst estimate for EPS of -16 cents.
- The company reported revenue of $40,000.
- This was 100% better than the analyst estimate for revenue of $20,000.
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/05/ibrx-stock-earnings-immunitybio-for-q1-of-2024/.
©2024 InvestorPlace Media, LLC